(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
The Most Enrapturing Authentic Milestones to Visit - 2US FDA unveils new pathway to approve personalized therapies
- 3How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV
- 4Find the Advantages of Careful Eating: Developing a Sound Connection with Food
- 5This Tiny Neon Frog Dwells in the Clouds
- The most effective method to Recognize an Excellent Lab Precious stone
- Discussion on deployment of foreign troops ongoing, two sources tell 'Post'
- Vote In favor of Feasible Way You Prescribe to Shop for Garments
- Cases of norovirus are on the rise just in time for the holiday season
- Executed Iranian nuclear scientist confessed to aiding Israel after torture, threats against mother
- Man triggers smoke bomb during failed crypto robbery
- IDF finds weapon of slain hostage Capt. Daniel Perez in booby-trapped Gaza compound
- AfD faction in western Germany ousts councilman for firebrand speech
- 2024 Eurovision winner Nemo returns trophy over Israel's participation
